KRTX — Karuna Therapeutics Share News
0.000.00%
Last trade - 00:00- $12.58bn
- $11.32bn
- $0.65m
Karuna Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Karuna Therapeutics Reports Q3 Loss Of $2.38 Per Share
Karuna Therapeutics Inc expected to post a loss of $2.11 a share - Earnings Preview
Brief: Psychogenics Announces Extension Of Ongoing Drug Discovery Collaboration With Karuna Therapeutics
U.S. RESEARCH ROUNDUP-Isoplexis, Seer, Wesco International
Karuna Therapeutics gains after upsized $750 mln equity raise
Brief: Karuna Therapeutics Announces Pricing Of Upsized Public Offering Of 3.5 Mln Shares At A Public Offering Price Of $215 Per Share
U.S. RESEARCH ROUNDUP- Avalara, Global Blood Therapeutics, Tyson Foods
Brief: Karuna Therapeutics Announces Proposed Public Offering Of Common Stock
U.S. STOCKS ON THE MOVE-Tiptree, Viatris, EV charging stocks
U.S. STOCKS ON THE MOVE-Elanco, Ceco, Monday.com
U.S. STOCKS ON THE MOVE-Signify Health, Tesla, Crypto firms
Karuna Therapeutics surges on positive results from schizophrenia drug trial
Brief: Karuna Therapeutics Announces Positive Results From Phase 3 EMERGENT-2 Trial Of KarXT In Schizophrenia
Karuna rises after FDA knocks back rival Acadia's antipsychotic drug
Karuna Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Karuna Therapeutics Reports First Quarter 2022 Financial Results And Provides General Business Update
Karuna Therapeutics Inc expected to post a loss of $2.11 a share - Earnings Preview
Cerevel's epilepsy, schizophrenia drug candidates look promising- Jefferies